Chenomx Announces Metabolite Database for ACD/Labs
News Dec 08, 2005
Advanced Chemistry Development, Inc. and Chenomx, Inc. have announced the immediate availability of the Chenomx Metabolite Database for ACD/Labs.
The Chenomx Metabolite Database for ACD/Labs contains 800MHz 1H NMR spectra for 265 of commonly found metabolites in urine and blood.
This database is designed to enable metabolomics researchers to identify a peak of interest in an NMR spectrum by searching against potential matches in the Chenomx Metabolite Database.
By making use of Chenomx’s database of NMR spectra, ACD/Labs’ metabolomics users will be able to perform routine peak identification directly from within ACD/1D NMR Manager.
This is in addition to the current capabilities of phase correction, baseline correction, and Intelligent Bucketing (or Binning) for batches of spectra.
Users can employ the ACD/Labs software to take them further by utilizing the Chenomx Metabolite database to help them identify some of the components of their biofluid samples.
Brent Lefebvre, NMR Product Manager for ACD/Labs, comments on the Chenomx Metabolite Database for ACD/Labs, "The decision to partner with Chenomx to supply the metabolite spectra for this database was an easy one."
"Chenomx is the leader in metabolic profiling by NMR and could provide our users with the best possible spectral database."
"Now, users will be able to spot a peak that is of interest to them in a biofluid spectrum, and easily search the database of common metabolites for it."
"If the metabolite is one that is commonly occuring, they will have just saved themselves an enormous amount of work searching disparate locations for this information."
Jack Newton, Director of Product Development for Chenomx, says, "Both Chenomx and ACD/Labs offer sophisticated software solutions to the rapidly growing NMR metabolomics community."
"Chenomx is happy to partner with ACD/Labs to provide this database to users that are looking to answer basic questions about what compounds are present in their NMR spectra."
"Although Chenomx offers a rich set of tools for performing targeted metabolite identification and quantitation, not all users require this level of sophistication."
"To address the needs of all of our users, we are proud to present this joint ACD/Labs-Chenomx solution."
About 422 million people around the world, including more than 30 million Americans, have diabetes. Obesity is the most significant risk factor for type 2 diabetes. yet about 30 percent of obese people do not develop type 2 diabetes or other metabolic conditions. New research aims to understand on a cellular level, how this separation occurs.READ MORE
Measuring hand grip can help identify youths who could benefit from lifestyle changes, says new research. While other studies have shown that muscle weakness as measured by grip strength is a predictor of unhealthy outcomes - including cardiovascular and metabolic diseases - this is the first to do so for adolescent health over time.READ MORE
Virtually all functions in our bodies require precise interactions between radically different types of molecules. A new study aims to understand how RNA molecules pair with intended protein partners. Researchers hope that they eventually will be able to predict and manipulate these partnerships that have been carved through millions of years of evolution.READ MORE